Special issue on circulating tumor DNA: Introductory editorial.

[1]  M. Heuser,et al.  Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia. , 2023, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[2]  E. Oki,et al.  Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer , 2023, Nature Medicine.

[3]  C. Sotiriou,et al.  Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. , 2022, JCO precision oncology.

[4]  C. Dive,et al.  Circulating tumour DNA — looking beyond the blood , 2022, Nature Reviews Clinical Oncology.

[5]  J. Ptak,et al.  Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. , 2022, The New England journal of medicine.

[6]  L. Pusztai,et al.  Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors , 2022, JCO precision oncology.

[7]  R. Rintoul,et al.  Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  H. Holte,et al.  Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. , 2021, Blood.

[9]  Fanshuang Zhang,et al.  Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC , 2021, Nature Communications.

[10]  A. Rosenwald,et al.  In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection. , 2021, Med.

[11]  S. Steinberg,et al.  Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma , 2021, Cancers.

[12]  Ash A. Alizadeh,et al.  Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA , 2021, Nature Biotechnology.

[13]  T. Powles,et al.  ctDNA guiding adjuvant immunotherapy in urothelial carcinoma , 2021, Nature.

[14]  K. Kong,et al.  Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  U. Platzbecker,et al.  Current challenges and unmet medical needs in myelodysplastic syndromes , 2021, Leukemia.

[16]  M. Roschewski,et al.  Circulating tumour DNA in B‐cell lymphomas: current state and future prospects , 2021, British journal of haematology.

[17]  Jing Wang,et al.  Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  S. Sleijfer,et al.  Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA , 2020, Molecular oncology.

[19]  K. Pantel,et al.  Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond , 2020, British Journal of Cancer.

[20]  D. Kurtz,et al.  Liquid biopsy in lymphoma: Molecular methods and clinical applications. , 2020, Cancer treatment reviews.

[21]  T. Haferlach.  Advancing leukemia diagnostics: Role of Next Generation Sequencing (NGS) in acute myeloid leukemia , 2020, Hematology reports.

[22]  J. Soh,et al.  Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study , 2020, Translational lung cancer research.

[23]  Rafael C. Schulman,et al.  Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring , 2020, Nature Medicine.

[24]  G. Salles,et al.  Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma. , 2020, JCO oncology practice.

[25]  C. Schiffer,et al.  European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia , 2020, Leukemia.

[26]  Helen M Moore,et al.  Harmonizing Cell-Free DNA Collection and Processing Practices through Evidence-Based Guidance , 2020, Clinical Cancer Research.

[27]  R. Chiu,et al.  The Biology of Cell-free DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB , 2020, American journal of human genetics.

[28]  W. Wilson,et al.  The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15‐ICML workshop on ctDNA , 2019, Hematological oncology.

[29]  F. Bidard,et al.  Impact of circulating tumor DNA early detection and serial monitoring in the management of stage I to III colorectal cancer. , 2019, Annals of translational medicine.

[30]  A. Bardelli,et al.  How liquid biopsies can change clinical practice in oncology. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  T. Fenske,et al.  Measurement of circulating tumor DNA to guide management of patients with lymphoma. , 2019, Clinical advances in hematology & oncology : H&O.

[32]  F. Jardin,et al.  Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study , 2019, Haematologica.

[33]  J. Martínez-López,et al.  Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies , 2019, International journal of molecular sciences.

[34]  H. Nielsen,et al.  Genome-wide cell-free DNA fragmentation in patients with cancer , 2019, Nature.

[35]  S. Shchegrova,et al.  Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer , 2019, JAMA oncology.

[36]  Tej D Azad,et al.  Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA) , 2019, Molecular Diagnosis & Therapy.

[37]  K. Shannon,et al.  Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  D. Rossi,et al.  Liquid biopsy in tissue-born lymphomas. , 2019, Swiss medical weekly.

[39]  Ali Rashidfarrokhi,et al.  Dnase1l3 deletion causes aberrations in length and end-motif frequencies in plasma DNA , 2018, Proceedings of the National Academy of Sciences.

[40]  Keval Patel,et al.  Enhanced detection of circulating tumor DNA by fragment size analysis , 2018, Science Translational Medicine.

[41]  A. Kohlmann,et al.  Current status and trends in the diagnostics of AML and MDS. , 2018, Blood reviews.

[42]  D. Rossi,et al.  Methods for Measuring ctDNA in Lymphomas. , 2018, Methods in molecular biology.

[43]  Ash A. Alizadeh,et al.  Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  R. Kurzrock,et al.  Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival , 2018, Annals of Surgical Oncology.

[45]  F. Cavalli,et al.  Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. , 2018, Blood.

[46]  M. Duffy,et al.  Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA , 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[47]  M. Boccadoro,et al.  Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia , 2018, Haematologica.

[48]  Y. Hasegawa,et al.  Clinical significance of disease‐specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma , 2017, Cancer science.

[49]  Ash A. Alizadeh,et al.  High-throughput sequencing for noninvasive disease detection in hematologic malignancies. , 2017, Blood.

[50]  P. Prorok,et al.  Prostate Cancer Screening - A Perspective on the Current State of the Evidence. , 2017, The New England journal of medicine.

[51]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[52]  F. Jardin,et al.  The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma , 2017, Oncotarget.

[53]  Ali Bashashati,et al.  Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study , 2016, PLoS medicine.

[54]  Ash A. Alizadeh,et al.  Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA , 2016, Science Translational Medicine.

[55]  F. Jardin,et al.  Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma , 2016, Haematologica.

[56]  R. Greil,et al.  Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones , 2016, Oncotarget.

[57]  A. Spencer,et al.  Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies , 2016, Cancer biology & medicine.

[58]  Ryan D. Morin,et al.  Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations , 2016, Oncotarget.

[59]  G. Schuurhuis,et al.  Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia , 2016, Leukemia.

[60]  F. Jardin,et al.  Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma , 2016, Leukemia & lymphoma.

[61]  Matthew W. Snyder,et al.  Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin , 2016, Cell.

[62]  K. Bartz-Schmidt,et al.  High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. , 2015, Blood.

[63]  Ash A. Alizadeh,et al.  Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. , 2015, Blood.

[64]  Mårten Fernö,et al.  Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease , 2015, EMBO molecular medicine.

[65]  L. Staudt,et al.  Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. , 2015, The Lancet. Oncology.

[66]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[67]  Steven J. M. Jones,et al.  Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. , 2013, Blood.

[68]  K. Pantel,et al.  Circulating tumor cells and circulating tumor DNA. , 2012, Annual review of medicine.

[69]  L. Larocca,et al.  Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  D. Campana.  Determination of minimal residual disease in leukaemia patients , 2003, British journal of haematology.

[71]  Valeri Vasioukhin,et al.  Point mutations of the N‐ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia , 1994, British journal of haematology.

[72]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[73]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.